PropThink: Safety Concerns with Kynamro Battering ISIS Ahead of Advisory Panel Vote

[ACN Newswire] – By Jake KingThe FDA has raised safety concerns about tumors spotted in patients treated with the developmental LDL-lowering therapy, Kynamro. The drug is under review after a New Drug Application was accepted … more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard